Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial
ConclusionsIn the per-protocol set, the high-hemoglobin group demonstrated better kidney outcomes than the low-hemoglobin group, suggesting a potential benefit of maintaining higher hemoglobin levels in patients with advanced CKD without diabetes.Clinical trial registrationClinicaltrials.gov (identifier: NCT01581073).
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research
More News: Aranesp | Chronic Kidney Disease | Clinical Trials | Diabetes | Endocrinology | Proteinuria | Study | Urology & Nephrology